Platinum Asset Management logo

Platinum Asset Management

Oceania, New South Wales, Australia, Sydney

Description

Platinum Asset Management is an Australian based fund manager which specialises in investing in international equities.

Investor Profile

Platinum Asset Management has made 5 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (60%)
  • Series B (20%)
  • Series Unknown (20%)

Country Focus

  • Australia (40%)
  • Germany (20%)
  • United States (20%)
  • Sweden (20%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Biopharma
  • Life Science
  • Clinical Trials
  • Oncology
  • Artificial Intelligence (Ai)
  • Machine Learning
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Platinum Asset Management frequently co-invest with?

Baillie Gifford
Europe, Edinburgh, City of, United Kingdom, Edinburgh
Co-Investments: 1
Altium Capital
North America, New York, United States, New York
Co-Investments: 1
BVCF
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Athena Capital (South Africa)
Africa, NA - South Africa, South Africa, Cape Town
Co-Investments: 1
Australian Ethical Investment
Oceania, New South Wales, Australia, Sydney
Co-Investments: 1
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 1
Jebsen Capital
Asia, Hong Kong Island, Hong Kong, Causeway Bay
Co-Investments: 1
MF
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 3
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 1

What are some of recent deals done by Platinum Asset Management?

Egetis Therapeutics AB

Stockholm, Stockholms Lan, Sweden

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development.

Health CareMedicalPharmaceutical
Post Ipo EquitySep 30, 2024
Amount Raised: $29,523,450
SpeeDx

Sydney, New South Wales, Australia

SpeeDx is a provider of innovative multiplex and isothermal amplification solutions for clinical diagnostics.

BiotechnologyHealth DiagnosticsMedical
Series UnknownFeb 28, 2023
Amount Raised: $26,000,000
Recursion Pharmaceuticals

Salt Lake City, Utah, United States

Recursion Pharmaceuticals is a biotech company that develops a drug discovery platform and pipeline with machine learning.

Artificial Intelligence (AI)BiotechnologyMachine LearningPharmaceuticalSoftwareTherapeutics
Post Ipo EquityOct 25, 2022
Amount Raised: $150,000,000
Immutep

Sydney, New South Wales, Australia

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.

BiotechnologyClinical TrialsHealth CareOncologyPharmaceutical
Post Ipo EquityJul 9, 2019
Amount Raised: $6,925,165
BioNTech

Mainz, Rheinland-Pfalz, Germany

BioNTech is a biopharmaceutical company that develops cancer therapeutics for infectious diseases.

BiopharmaBiotechnologyLife SciencePharmaceutical
Series BJul 9, 2019
Amount Raised: $325,000,000